NAFLD
Clinical trials for NAFLD explained in plain language.
Never miss a new study
Get alerted when new NAFLD trials appear
Sign up with your email to follow new studies for NAFLD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a hormone pill shrink fatty liver? small study hints at possibility
Disease control CompletedThis pilot study tested a drug called ibutamoren in 12 adults with nonalcoholic fatty liver disease (NAFLD). The goal was to see if it could lower fat in the liver. Participants took the drug for 6 months, and researchers measured liver fat using a special MRI. The study is compl…
Matched conditions: NAFLD
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 17, 2026 02:26 UTC
-
Can a tweak in diet plus exercise reverse fatty liver in 3 months?
Disease control CompletedThis study looked at 36 adults with obesity and non-alcoholic fatty liver disease (NAFLD). Participants followed one of two low-calorie Mediterranean diet plans, with different amounts of carbs and fats, plus a moderate exercise program. After 3 months, researchers checked liver …
Matched conditions: NAFLD
Phase: NA • Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Disease control
Last updated May 17, 2026 02:22 UTC
-
New drug shows promise against fatty liver in early trial
Disease control CompletedThis study tested a new medicine called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could reduce liver fat by at least 30% over 48 weeks compared to a placebo. The trial also checked safety and other liver hea…
Matched conditions: NAFLD
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated May 17, 2026 02:20 UTC
-
Can a two-pill cocktail reverse liver damage from fatty liver disease?
Disease control CompletedThis study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. Thirty adults with biopsy-confirmed fibrosis took the drugs or a placebo for 21 weeks. The main go…
Matched conditions: NAFLD
Phase: PHASE1, PHASE2 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
Plant power: phytosterol supplement shows promise for fatty liver
Disease control CompletedThis study looked at whether taking a natural plant supplement called phytosterol can help people with nonalcoholic fatty liver disease (NAFLD). 27 adults took the supplement for 3 months. Researchers measured changes in liver enzymes, cholesterol, insulin, and inflammation. The …
Matched conditions: NAFLD
Phase: NA • Sponsor: University of Jordan • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Blood tests may replace painful liver biopsies for diabetes patients
Knowledge-focused CompletedThis study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect advanced liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to a specialized ultrasound (FibroScan) and, in some cases, liver biopsy. The go…
Matched conditions: NAFLD
Phase: NA • Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 02:23 UTC
-
Liver disease and COVID shots: new study checks immune response
Knowledge-focused CompletedThis completed study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. Researchers measured antibody levels and tracked COVID-19 infections over 6 months in 233 adults. The goal was to see if liver disease severity…
Matched conditions: NAFLD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated May 17, 2026 02:23 UTC